Table 2.
Performance of previously published protein prognostic biomarker candidates in OSskcm
| Gene symbol | Literature data | Validation results | ||||||
|---|---|---|---|---|---|---|---|---|
| References | n | Survival endpoint | Prognostic significance of high expression | HR (95%CI) | Log-rank P value | Datasets | Cut off | |
| KLK7 | [20] | 45 | OS | Good | 2.65 (1.27–5.53)† | 0.0095 | GSE17275 | Upper 25% |
| 3.60 (1.48–8.80)† | 0.0049 | GSE19234 | Upper 25% | |||||
| 1.93 (1.40–2.65)† | < 0.0001 | TCGA | Upper 25% | |||||
| MITF | [29] | 200 | OS | Poor | 1.43 (1.09–1.87)† | 0.0104 | TCGA | Upper 50% |
| 3.46 (1.42–8.42)† | 0.0063 | GSE19234 | Upper 50% | |||||
| 3.33 (1.18–9.41)† | 0.0230 | GSE98394 | Upper 50% | |||||
| KIF20A | [30] | 61 | RFS | Poor | 2.17 (1.12–4.20)† | 0.0218 | GSE22155 | Upper 25% |
| 2.56 (1.20–5.47)† | 0.0151 | GSE50509 | Upper 25% | |||||
| 3.21 (1.26–8.20)† | 0.0147 | GSE98394 | Upper 25% | |||||
| 2.44 (1.02–5.83)† | 0.0454 | GSE19234 | Upper 25% | |||||
| CTHRC1 | [31] | 35 | OS | Poor | 3.41 (1.31–8.89)† | 0.0122 | GSE98394 | Upper 25% |
| TFAP2A | [32] | Nearly 600 | DSS | Poor | 1.59 (1.03–2.47)‡ | 0.0379 | GSE65904 | Upper 25% |
| ATF2 | [33] | 544 | OS | Poor | 3.05 (1.56–5.97)† | 0.0012 | GSE22155 | Upper 25% |
| NCOA3 | [34] | 343 | RFS and DSS | Poor | 1.79 (1.17–2.74)‡ | 0.0071 | GSE65904 | Upper 25% |
| BCL2 | [35] | 339 | OS | Good | 0.21 (0.04–0.97)† | 0.0458 | GSE22155 | Upper 25% |
| BIRC5 | [36] | 50 | DFS and OS | Poor | 3.73 (1.44–9.67)† | 0.0068 | GSE98394 | Upper 25% |
| MCAM | [37] | 76 | OS | Poor | 4.66 (1.78–12.18)† | 0.0017 | GSE19234 | Upper 25% |
| PLAT | [38] | 214 | DMFI and OS | Poor | 2.24 (1.16–4.34)† | 0.0164 | GSE22155 | Upper 25% |
| 3.88 (1.47–10.24)† | 0.0063 | GSE98394 | Upper 25% | |||||
| NOS2 | [39] | 132 | DSS and OS | Poor | 1.41 (1.07–1.85)† | 0.0131 | TCGA | Upper 50% |
| CDKN1B | [40] | 383 | DSS and OS | Poor | 0.48 (0.24–0.95)† | 0.0341 | GSE22155 | Upper 25% |
| 0.69 (0.50–0.95)† | 0.0235 | TCGA | Upper 25% | |||||
| BCL6 | [41] | 88 | 6-year OS | Poor | 0.57 (0.40–0.80)† | 0.0011 | TCGA | Upper 25% |
| FXYD5 | [42] | 115 | OS | Poor | 3.10 (1.24–7.76)† | 0.0159 | GSE19234 | Upper 25% |
| DDIT3 | [43] | 106 | OS | Good | 5.74 (2.18–15.13)† | 0.0004 | GSE98394 | Upper 25% |
| MCAT | [44] | 1270 | DFI and OS | Poor | 5.75 (1.26–26.10)† | 0.0236 | GSE22155 | Upper 25% |
| 4.51 (1.72–11.82)† | 0.0021 | GSE98394 | Upper 25% | |||||
| CTNNB1 | [45] | 202 | DSS | Good | 1.55 (1.02–2.37)‡ | 0.0412 | GSE65904 | Upper 25% |
| 1.75 (1.15–2.67)‡ | 0.0088 | GSE65904 | Upper 25% | |||||
| AKT1 | [46] | 222 | 5-year DSS or OS | Poor | 6.41 (2.39–17.23)† | 0.0002 | GSE98394 | Upper 25% |
| 1.53 (1.13–2.06)† | 0.0056 | TCGA | Upper 25% | |||||
| RUNX3 | [47] | 421 | 5-year OS | Good | 3.75 (1.36–10.33)† | 0.0107 | GSE50509 | Upper 25% |
| 5-year DSS | 1.81 (1.18–2.76)‡ | 0.0062 | GSE65904 | Upper 25% | ||||
| BBC3 | [48] | 158 | 5-year DSS or OS | Poor | 3.62 (1.38–9.52)† | 0.0092 | GSE98394 | Upper 25% |
| MMP2 | [49] | 157 | DSS and RFS | Poor | 1.41 (1.06–1.89)‡ | 0.0197 | TCGA | Upper 50% |
| SPP1 | [50] | 345 | RFS | Poor | 9.42 (3.46–25.67)† | < 0.0001 | GSE98394 | Upper 25% |
| TNC | [51] | 98 | DFS | Poor | 1.54 (1.01–2.34)‡ | 0.0434 | GSE65904 | Upper 25% |
| CCNA2 | [52] | 245 | RFS | Poor | 2.23 (1.02–4.88)† | 0.0437 | GSE50509 | Upper 25% |
| RGS1 | [53] | 40 | DSS | Poor | 2.74 (1.03–7.24)† | 0.0425 | GSE98394 | Upper 25% |
| 3.24 (1.31–8.00)† | 0.0110 | GSE19234 | Upper 25% | |||||
| 2.66 (1.07–6.65)† | 0.0357 | GSE19234 | Upper 25% | |||||
| SPARC | [54] | 112 | DFS | Poor | 2.78 (1.21–6.34)† | 0.0154 | GSE50509 | Upper 25% |
| CXCR4 | [55] | 71 | DFS and OS | Poor | 0.70 (0.51–0.97)† | 0.0315 | TCGA | Upper 25% |
| RBM3 | [56] | 246 | OS | Good | NS | NS | – | – |
| EPAS1 | [57] | 46 | DSS | Poor | 3.51 (1.56–7.91)† | 0.0024 | GSE50509 | Upper 25% |
NS not significance, RFS recurrence-free survival, DFS disease-specific survival, DFI disease-free interval, DMFI distant metastasis-free interval
†,‡HR (95%CI) and Log-rank P value of overall survival (OS) and disease-specific survival (DSS)